Bio-Techne Corp Dossier
Qualitative Analysis
Business overview
Bio-Techne Corporation (NASDAQ: TECH) is a leading global life sciences company that develops, manufactures, and sells high-quality biotechnology reagents, analytical instruments, and precision diagnostics. Celebrating 50 years of empowering the scientific and diagnostic communities, the company organizes its extensive portfolio of over 500,000 products into three customer-focused brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics. These brands support the entire scientific journey from early-stage discovery and translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs approximately 3,100 people, serving academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Completed a $50 million expansion of large-scale GMP protein production to supply clinical-grade cytokines and growth factors for CAR-T and advanced cell therapies.
Expected impact: Enables transition from research-use-only to commercial-stage supplier, capturing higher-value, longer-duration contracts in the pharmaceutical supply chain.
Following the integration of the Lunaphore COMET platform, launching hyperplex multi-omic panels to address spatial proteomics and transcriptomics.
Expected impact: Aims to capture a significant share of the estimated $12 billion spatial biology total addressable market (TAM).
Divesting non-core, lower-margin, or high-sales-intensity businesses (such as Exosome Diagnostics) to focus resources on high-margin tools, reagents, and automated platforms.
Expected impact: Delivers an immediate uplift to the company's operating margin profile (Diagnostics and Spatial Biology segment operating margin increased from 3.9% to 10.4% in Q2 FY2026 post-divestiture).
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of a developer of microfluidic-based instruments for spatial biology and tumor analysis, enhancing Bio-Techne's spatial proteomics capabilities via the COMET platform.
Financial impact: COMET platform posted nearly 50% revenue growth in fiscal year 2025, establishing spatial biology as a primary growth pillar.
Strategic Partnerships
Bio-Techne participated in Spear Bio's $45 million Series A funding round in 2024 and subsequently signed a strategic partnership in July 2025 to distribute Spear Bio's next-generation ultrasensitive immunoassays for low-abundance neurology biomarkers (e.g., pTau 217, GFAP, Nf-L) supporting Alzheimer's research.
Terms: $15 million equity investment in fiscal year 2025; exclusive distribution terms undisclosed.
Bio-Techne holds a 20% ownership stake in Wilson Wolf, a leader in cell therapy manufacturing tools (G-Rex bioreactors). The partnership bridges research-grade reagents and clinical manufacturing tools, driving reagent pull-through.
Terms: Bio-Techne plans to fully acquire the remaining 80% ownership of Wilson Wolf by the end of calendar year 2027.